Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT06167642
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Ofatumumab — DRUG
    Ofatumumab therapy is part of the patient's clinical care and is not given as part of the study

Study Details

This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in people with relapsing-remitting MS (RMS), according to baseline serum neurofilament light chain (sNfL) levels.

Key Dates

Start date
May 22, 2023
Status verified
Jun 2026
Primary completion
Mar 31, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
75 participants (estimated)

Arms

  • Arm: People with RMS due to commence or already receiving ofatumumab therapy
    75 people with RMS due to commence or already receiving ofatumumab therapy within 60 days of baseline.

Primary Outcome Measure

Ganglion cell inner plexiform (GCIP) atrophy in RMS relative to HCs, according to baseline sNfL levels [ Time Frame: at least 12 months for up to 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Johns HopkinsBaltimoreMaryland21287-

Find similar trials in Baltimore, MD

By condition
Multiple sclerosis
By specialty
NeurologyBrain disordersAutoimmune disease
By research site
Johns Hopkins· Baltimore, MD

Related Studies